Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Pinto MD, Greenblatt AM, Williams BL, Kaplin AI. Exploring the mechanism of the clinical encounter on depressive symptoms in young adults: a path analysis. Issues Ment Health Nurs. 2017 Jul;38(7):533-9. doi: 10.1080/01612840.2017.1305023.
Greenblatt AM, Pinto MD, Higgins MK, Berg CJ. Exploring the relationships among level of contact, nature of contact, and mental illness stigma in adolescent girls. Issues Ment Health Nurs. 2016 Jan;37(1):10-8. doi: 10.3109/01612840.2015.1087604
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.